Video-on-Demand Library

This content is restricted to members of PSI. If you are already a member please login. To join PSI or to see all the benefits of membership click here.

18 November 2019

José Pinheiro, Björn Bornkamp, Tobias Mielke, France Mentré, Rob Hemmings

Longitudinal data, i.e. data that arises from repeated observations of the variable over a period of time, has long been put forward as one way to improve to the efficiency of drug development. However, even though there is a rich statistical methodology for longitudinal data, there is no full, wholehearted uptake of these methods in pharmaceutical statistics. The purpose of this webinar is to explore the use of longitudinal modelling across drug development, highlighting its opportunities (such as usage as primary analyses, or for improved decision making at interim analyses) and caveats. One important aspect to be discussed is the evaluation of the efficiency of (parametric) longitudinal modelling versus standard cross-sectional approaches, and factors based upon which one approach might be preferable over the other.

Topic(s)

Upcoming Events

Latest Jobs